| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 17, 2011
MINNEAPOLIS, Oct 17, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for its Aquamantys(R)3...
-
Oct 17, 2011
MINNEAPOLIS, Oct 17, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced that its Board of Directors unanimously voted to elect Michael O. Leavitt, founder and chairman of Leavitt...
-
Oct 13, 2011Integrity(R) Coronary Stent Redefines Deliverability with Continuous Sinusoid Technology; Endurant(R) AAA Stent Graft Expands Applicability of Endovascular Aortic Repair
MINNEAPOLIS, Oct 13, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced plans to introduce two of its next-generation cardiovascular devices in Japan, the world's second largest...
-
Oct 10, 2011First Ever Randomized, Controlled Clinical Trial in Persistent Atrial Fibrillation (AF) Patients
VENICE, Italy & MINNEAPOLIS, Oct 10, 2011 (BUSINESS WIRE) -- Medtronic, Inc.(NYSE: MDT) today announced results from its Tailored Treatment of Permanent Atrial Fibrillation (TTOP-AF) clinical...
-
Sep 27, 2011Study will evaluate new therapy option for patients suffering from valvular heart disease
MINNEAPOLIS, Sep 27, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced the start of the Engager(TM) European Pivotal Trial to pursue CE (Conformité Européenne) Mark for the...